Metabolic risk factors for development of neuroendocrine tumors

doi:10.16138/j.1673-6087.2023.04.008

Abstract

CLC Number:

R736

ZHANG Jie, BI Yufang. Metabolic risk factors for development of neuroendocrine tumors[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 251-255.

References 49

[1]	Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States[J]. JAMA Oncol, 2017, 3(10): 1335-1342. doi: 10.1001/jamaoncol.2017.0589 pmid: 28448665
[2]	Muscogiuri G, Altieri B, Albertelli M, et al. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective[J]. Endocrine, 2020, 69(2): 441-450. doi: 10.1007/s12020-020-02331-3 pmid: 32468269
[3]	Ruggeri RM, Benevento E, De Cicco F, et al. Neuroendocrine neoplasms in the context of inherited tumor syndromes[J]. J Endocrinol Invest, 2023, 46(2): 213-234. doi: 10.1007/s40618-022-01905-4
[4]	Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(7): 844-860. doi: S0923-7534(20)36394-8 pmid: 32272208
[5]	Oronsky B, Ma PC, Morgensztern D, et al. Nothing but NET: a review of neuroendocrine tumors and carcinomas[J]. Neoplasia, 2017, 19(12): 991-1002. doi: S1476-5586(17)30347-0 pmid: 29091800
[6]	Díez M, Teulé A, Salazar R. Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment[J]. Ann Gastroenterol, 2013, 26(1): 29-36.
[7]	Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States[J]. J Clin Oncol, 2008, 26(18): 3063-3072. doi: 10.1200/JCO.2007.15.4377 URL
[8]	Thorson A, Biorck G, Bjorkman G, et al. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome[J]. Am Heart J, 1954, 47(5): 795-817. pmid: 13158264
[9]	Riihimäki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases in neuroendocrine tumors[J]. Int J Cancer, 2016, 139(12): 2679-2686. doi: 10.1002/ijc.30400 pmid: 27553864
[10]	Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours[J]. Lancet Oncol, 2008, 9(1): 61-72. doi: 10.1016/S1470-2045(07)70410-2 pmid: 18177818
[11]	Hassan MM, Phan A, Li D, et al. Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study[J]. Int J Cancer, 2008, 123(4): 867-873. doi: 10.1002/ijc.23529 pmid: 18491401
[12]	Hassan MM, Phan A, Li D, et al. Family history of cancer and associated risk of developing neuroendocrine tumor[J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(4): 959-965. doi: 10.1158/1055-9965.EPI-07-0750 URL
[13]	Halfdanarson TR, Bamlet WR, McWilliams RR, et al. Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study[J]. Pancreas, 2014, 43(8): 1219-1222. doi: 10.1097/MPA.0000000000000234 URL
[14]	Cigrovski Berković M, Catela Ivković T, Marout J, et al. Interleukin 1β gene single-nucleotide polymorphisms and susceptibility to pancreatic neuroendocrine tumors[J]. DNA Cell Biol, 2012, 31(4): 531-536. doi: 10.1089/dna.2011.1317 pmid: 21988351
[15]	Kaerlev L, Teglbjaerg PS, Sabroe S, et al. Occupational risk factors for small bowel carcinoid tumor: a European population-based case-control study[J]. J Occup Environ Med, 2002, 44(6): 516-522. pmid: 12085477
[16]	Capurso G, Falconi M, Panzuto F, et al. Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients[J]. Am J Gastroenterol, 2009, 104(12): 3034-3041. doi: 10.1038/ajg.2009.466 pmid: 19690522
[17]	Karakaxas D, Gazouli M, Coker A, et al. Genetic polymorphisms of inflammatory response gene TNF-α and its influence on sporadic pancreatic neuroendocrine tumors predisposition risk[J]. Med Oncol, 2014, 31(10): 241. doi: 10.1007/s12032-014-0241-z pmid: 25213764
[18]	Berković M, Cacev T, Zjacić Rotkvić V, et al. TNF-alpha promoter single nucleotide polymorphisms in gastro-enteropancreatic neuroendocrine tumors[J]. Neuroendocrin-ology, 2006, 84(5): 346-352.
[19]	Burnik FS, Yalçin S. NFKB1-94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors[J]. Chemotherapy, 2009, 55(5): 381-385. doi: 10.1159/000237744 URL
[20]	Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors[J]. Cancer, 2003, 97(4): 934-959. doi: 10.1002/cncr.11105 pmid: 12569593
[21]	Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?[J]. Curr Oncol Rep, 2021, 23(4): 43. doi: 10.1007/s11912-021-01029-7 pmid: 33719003
[22]	Ohtani N, Yoshimoto S, Hara E. Obesity and cancer: a gut microbial connection[J]. Cancer Res, 2014, 74(7): 1885-1889. doi: 10.1158/0008-5472.CAN-13-3501 pmid: 24638983
[23]	Tsuei J, Chau T, Mills D, et al. Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer[J]. Exp Biol Med (Maywood), 2014, 239(11): 1489-1504. doi: 10.1177/1535370214538743 pmid: 24951470
[24]	Herrera-Martínez AD, Pedraza-Arevalo S, L-López F, et al. Type 2 diabetes in neuroendocrine tumors: are biguanides and statins part of the solution?[J]. J Clin Endocrinol Metab, 2019, 104(1): 57-73. doi: 10.1210/jc.2018-01455 pmid: 30265346
[25]	Santos AP, Santos AC, Castro C, et al. Visceral obesity and metabolic syndrome are associated with well-differentiated gastroenteropancreatic neuroendocrine tumors[J]. Cancers (Basel), 2018, 10(9): 293. doi: 10.3390/cancers10090293 URL
[26]	Pyo JH, Hong SN, Min BH, et al. Evaluation of the risk factors associated with rectal neuroendocrine tumors: a big data analytic study from a health screening center[J]. J Gastroenterol, 2016, 51(12): 1112-1121. pmid: 27025841
[27]	Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr relat cancer[J]. Endocr Relat Cancer, 2009, 16(4): 1103-1123. doi: 10.1677/ERC-09-0087 URL
[28]	Gallo M, Ruggeri RM, Muscogiuri G, et al. Diabetes and pancreatic neuroendocrine tumours: which interplays, if any?[J]. Cancer Treat Rev, 2018, 67: 1-9. doi: S0305-7372(18)30057-4 pmid: 29746922
[29]	Mottin CC, Cruz RP, Gomes Thomé G, et al. Carcinoid tumors and morbid obesity[J]. Obes Surg, 2009, 19(2): 247-249. doi: 10.1007/s11695-008-9541-8 pmid: 18506551
[30]	Al-Harbi O, Shakir M, Al-Brahim N. Gastric carcinoid and obesity: association or coincidence? Report of two cases and literature review[J]. Case Rep Gastrointest Med, 2013, 2013: 848075.
[31]	Perryman S, Kaltenbach T, Eisenberg D. Preoperative finding of gastric neuroendocrine tumor (gastric carcinoid) in a patient evaluated for bariatric surgery[J]. Surg Obes Relat Dis, 2011, 7(5): e18-e20. doi: 10.1016/j.soard.2010.11.005 URL
[32]	Cross AJ, Hollenbeck AR, Park Y. A large prospective study of risk factors for adenocarcinomas and malignant carcinoid tumors of the small intestine[J]. Cancer Causes Control, 2013, 24(9): 1737-1746. doi: 10.1007/s10552-013-0251-8 URL
[33]	Zhan HX, Cong L, Zhao YP, et al. Risk factors for the occurrence of insulinoma: a case-control study[J]. Hepatobiliary Pancreat Dis Int, 2013, 12(3): 324-328. doi: 10.1016/S1499-3872(13)60051-X URL
[34]	Vitale G, Dicitore A, Barrea L, et al. From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?[J]. Rev Endocr Metab Disord, 2021, 22(3): 511-525. doi: 10.1007/s11154-020-09589-y
[35]	Leoncini E, Carioli G, La Vecchia C, et al. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis[J]. Ann Oncol, 2016, 27(1): 68-81. doi: 10.1093/annonc/mdv505 pmid: 26487581
[36]	Barrea L, Altieri B, Muscogiuri G, et al. Impact of nutritional status on gastroenteropancreatic neuroendocrine tumors (GEP-NET) aggressiveness[J]. Nutrients, 2018, 10(12): 1854. doi: 10.3390/nu10121854 URL
[37]	Bostan H, Duger H, Akhanli P, et al. Cushing’s syndrome due to adrenocorticotropic hormone-secreting metastatic neuroendocrine tumor of unknown primary origin: a case report and literature review[J]. Hormones (Athens), 2022, 21(1): 147-154. doi: 10.1007/s42000-021-00316-z
[38]	Zainal A, Akinsola O, Rajamani K. Cushing syndrome secondary to primary neuroendocrine lung carcinoma[J]. Case Rep Endocrinol, 2019, 2019: 1989260.
[39]	Wu Y, Yue L, Li J, et al. Cushing’s syndrome secondary to typical pulmonary carcinoid with mutation in BCOR gene: a case report[J]. Medicin (Baltimore), 2017, 96(34): e7870.
[40]	Kamp K, Alwani RA, Korpershoek E, et al. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors[J]. Eur J Endocrinol, 2016, 174(3): 271-280. doi: 10.1530/EJE-15-0968 pmid: 26643855
[41]	Jyotsna VP, Malik E, Birla S, et al. Novel MEN 1 gene findings in rare sporadic insulinoma—a case control study[J]. BMC Endocr Disord, 2015, 15: 44. doi: 10.1186/s12902-015-0041-2 pmid: 26307114
[42]	Maric A, Katalinic D, Belovari M, et al. Insulinoma and extreme obesity in a patient with MEN1 syndrome[J]. Acta Gastroenterol Belg, 2010, 73(2): 296-297. pmid: 20690576
[43]	Lee JM, Shin J, Kim S, et al. Rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, and neuroendocrine tumors (ROHHADNET) syndrome[J]. Biomed Res Int, 2018, 2018: 1250721.
[44]	Raccosta L, Fontana R, Maggioni D, et al. The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils[J]. J Exp Med, 2013, 210(9): 1711-1728. doi: 10.1084/jem.20130440 URL
[45]	Wu AH, Yu MC, Mack TM. Smoking, alcohol use, dietary factors and risk of small intestinal adenocarcinoma[J]. Int J Cancer, 1997, 70(5): 512-517. pmid: 9052748
[46]	Cross AJ, Leitzmann MF, Subar AF, et al. A prospective study of meat and fat intake in relation to small intestinal cancer[J]. Cancer Res, 2008, 68(22): 9274-9279. doi: 10.1158/0008-5472.CAN-08-2015 pmid: 19010900
[47]	Barrea L, Muscogiuri G, Modica R, et al. Cardio-metabolic indices and metabolic syndrome as predictors of clinical severity of gastroenteropancreatic neuroendocrine tumors[J]. Front Endocrinol (Lausanne), 2021, 12: 649496. doi: 10.3389/fendo.2021.649496 URL
[48]	Feola T, Puliani G, Sesti F, et al. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study[J]. J Endocrinol Invest, 2022, 45(4): 849-857. doi: 10.1007/s40618-021-01715-0 pmid: 35040099
[49]	Good ML, Malekzadeh P, Ruff SM, et al. Surgical resection of pheochromocytomas and paragangliomas is associated with lower cholesterol levels[J]. World J Surg, 2020, 44(2): 552-560. doi: 10.1007/s00268-019-05175-9 pmid: 31531722

Metabolic risk factors for development of neuroendocrine tumors

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 49

Related Articles 3

Recommended Articles

Metrics

Comments

[1]	NING Guang. Precision treatment in endocrine tumors [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 225-226.
[2]	YE Lei, WANG Weiqing. Establishment and application of molecular diagnostic platform for endocrine tumors [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 227-229.
[3]	ZHANG Jie, LU Jieli. Clinical diagnosis and treatment progress of hypoglycemia caused by non-islet cell tumors [J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 256-260.